Drug intelligence / Profile preview

DKF-5122

Development stage: Phase 1
Lead developer: Dongkook Pharmaceutical

Overview

DKF-5122 is a novel antifungal agent under development by Dongkook Pharmaceutical. It is classified as a new molecular entity and has been investigated primarily for the treatment of invasive fungal infections (mycoses) and febrile neutropenia. The precise mechanism of action remains undefined, but it is categorized broadly as an antifungal. Clinical development has included phase 1 trials in South Korea, with no current reports of advancement beyond this stage or regulatory approval in any country[1][3][4][5].

Beyond the preview

Go deeper on DKF-5122.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DKF-5122.

Explore the full profile